Key facts
- Epalex’s last known valuation is $145.0M (Nov 2025).
- It has raised $30.9M across 5 recorded rounds; the latest was Seed Round ($1.2M) in Oct 2025.
- Notable investors include University of California.
- Epalex has filed 5 Form Ds with the SEC since 2018, most recently Dec 2024 ($4.0M sold to 1 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 5 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Epalex
Funding rounds
5 roundsAbout Epalex
Operator of a specialty pharmaceutical development company intended to create novel therapies for patients with neurological disorders. The company is developing novel oral treatments for migraines and epilepsy, enabling patients to have a sustainable way of treating their generalized epilepsies, migraines and acute repetitive seizures.
- Sector
- Healthcare
- HQ
- Mountain View, CA, United States
- Founded
- 2009
- Employees
- 5
- Website
- epalex.com/
- Ownership
- Privately Held (backing)
Epalex doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Epalex shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Epalex in its N-PORT filings yet. We sweep new filings monthly.